Translating Advanced Cancer Research into Personalized, Passionate Treatment.
John Wayne Cancer Institute at Providence Saint John’s Health Center is a cancer research institute dedicated to the understanding, diagnosis, and innovative treatment of cancer in order to eliminate patient suffering and prolong survival.Read More
Steven O’Day, MD, New Executive Director of the John Wayne Cancer Institute & Director of Providence Los Angeles Regional Research
Dr. O’Day is world-renowned in the field of medical oncology and his leadership capabilities make him the ideal person to lead the cancer and research efforts on our campus and in our region.
Clinical trials have always been an important part of John Wayne Cancer Institute. Our institute led the trials that established sentinel lymph node biopsy as the standard of care for melanoma and breast care and pioneered immunotherapy as treatment for melanoma. Today, our patients continue to have access to the latest treatments and trials. We are at the forefront of studying the biology of cancer as well as expanding treatment for those suffering world-wide.Learn More
Attracting Patients from Around the World
As international leaders in cancer care, the John Wayne Cancer Institute attracts patients from all over the country and around the world. Seeing such a large number of patients, our team of experts bring a high level of experience to every aspect of your treatment. We’re with you from diagnosis through cure and have a team approach for better outcomes.Meet our Experts
Complex Surgical Oncology Fellowship
With a longstanding history of excellence in multidisciplinary cancer care and education, the John Wayne Cancer Institute continues to be a leader in training the next generation of leaders in the field of surgical oncology.Learn more about this fellowship
Urologic Oncology Fellowship
The JWCI provides world class, multidisciplinary training in genitourinary malignancies and urologic oncology research with innovative and cutting edge technology.Learn more about this fellowship
This training program focuses on endonasal endoscopic and keyhole surgical approaches, neuro-endoscopy, pituitary tumor management and multimodality neuro-oncology treatments.Learn more about this fellowship
Postdoctoral Lab-Based Translational Molecular Medicine Fellowship
As pioneers in translational studies on “liquid biopsies” involving circulating tumor cells in multiple types of solid tumors, the fellowship program also consists of studying epigenetic mechanisms regulating solid tumor as well as pharmacogenomics and immunogenomic based prediction of response to therapy.Learn more about this fellowship
Latest News & Events
Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody
In collaboration with Agenus, Dr. Steven O’Day, Executive Director of the John Wayne Cancer Institute & Cancer Clinic, is working on a combination study with two novel CTLA-4 and PD-1 immunotherapy drugs for patients with advanced cancers. Dr. O’Day’s site treated the first patient in the world with the novel CTLA-4 Inhibitor, AGEN1181. Now his site has treated the first patient with AGEN1181 in combination with AGEN2034, a PD-1 inhibitor. This promising combination of immunotherapy is at the forefront of testing a variety of advanced cancers for all solid tumors.
Novel Epigenomic and Oncogenic Drivers of Melanoma Metastasis and Therapeutic Resistance
The department of Translational Molecular Medicine and the JWCI Sequencing Center under Dr. Dave Hoon, received a $4.5 million grant for Novel Epigenomic and Oncogenic Drivers of Melanoma Metastasis and Therapeutic Resistance and new approaches of next generation sequencing for various solid tumors from the Adeleson Melanoma Research Foundation for three years. This will be 8 years of continual funding in a multi-Institute collaborative funding program in cancer and neuro-related diseases.
Lipid–Polymer Hybrid Nanoparticles as a Next-Generation Drug Delivery Platform: State of the Art, Emerging Technologies, and Perspectives
Learn about Lipid–polymer hybrid nanoparticles (LPHNPs) and the recent key advancements for future clinical possibilities, from Venkata Yenugonda, M.Phil, Ph.D., Associate Professor, Department of Translational Neurosciences & Neurotherapeutics, and Director, Drug Discovery and Nanomedicine.